Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 3Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3CNS 1

Conditions

Neuroendocrine Tumors 3Small Cell Lung Carcinoma 2Meningioma 2Medulloblastoma 2Lung Neoplasms 2Breast Neoplasms 2Vipoma 1Somatostatinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Pinealoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Insulinoma 1Hodgkin Disease 1Growth Hormone-Secreting Pituitary Adenoma 1Glucagonoma 1Gliosarcoma 1Glioma, Subependymal 1

Interventions

Everolimus 17lutetium Lu 177 dotatate 7Octreotide 7pasireotide 6lanreotide 6gallium Ga 68 dotatate 5Temozolomide 5Sunitinib 5Positron Emission Tomography Computed Tomography 5surufatinib 4pembrolizumab 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03197012 2020-07-07

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

University of California, San Francisco

Phase EARLY_PHASE1 Completed
10 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04296149 2020-03-05

RADIONET

European Institute of Oncology

Phase 2 Completed
5 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡